Peter Bouwman
Overview
Explore the profile of Peter Bouwman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
3344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khalizieva A, Moser S, Bouwman P, Jonkers J
Genes Dev
. 2024 Nov;
39(1-2):86-108.
PMID: 39510841
The discovery of and as tumor susceptibility genes and their role in genome maintenance has transformed our understanding of hereditary breast and ovarian cancer. This review traces the evolution of...
2.
Niemeijer M, Wiecek W, Fu S, Huppelschoten S, Bouwman P, Baze A, et al.
Environ Health Perspect
. 2024 Mar;
132(3):37005.
PMID: 38498338
Background: Understanding the variability across the human population with respect to toxicodynamic responses after exposure to chemicals, such as environmental toxicants or drugs, is essential to define safety factors for...
3.
Audebert M, Assmann A, Azqueta A, Babica P, Benfenati E, Bortoli S, et al.
Front Toxicol
. 2023 Jul;
5:1220998.
PMID: 37492623
Carcinogenic chemicals, or their metabolites, can be classified as genotoxic or non-genotoxic carcinogens (NGTxCs). Genotoxic compounds induce DNA damage, which can be detected by an established and battery of genotoxicity...
4.
van der Noord V, van der Stel W, Louwerens G, Verhoeven D, Kuiken H, Lieftink C, et al.
Breast Cancer Res
. 2023 May;
25(1):51.
PMID: 37147730
Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with limited treatment options and poor clinical prognosis. Inhibitors of transcriptional CDKs are currently under thorough investigation for application...
5.
Bouwman P, van der Heijden I, van der Gulden H, de Bruijn R, Braspenning M, Moghadasi S, et al.
Clin Cancer Res
. 2022 Oct;
28(20):4588.
PMID: 36239017
No abstract available.
6.
Ratz L, Brambillasca C, Bartke L, Huetzen M, Goergens J, Leidecker O, et al.
Breast Cancer Res
. 2022 Jun;
24(1):41.
PMID: 35715861
Background: The majority of BRCA1-mutant breast cancers are characterized by a triple-negative phenotype and a basal-like molecular subtype, associated with aggressive clinical behavior. Current treatment options are limited, highlighting the...
7.
Duijndam B, Tedeschi M, van der Stel W, van den Hoorn T, van der Burg B, Bouwman P, et al.
Toxicol In Vitro
. 2022 Mar;
81:105348.
PMID: 35307500
Estrogen receptor alpha (ERα) is often a primary target of endocrine disrupting chemicals (EDCs) and therefore several biochemical and cell-based assays for the detection of chemicals with estrogenic properties have...
8.
Pulver E, Mukherjee C, van de Kamp G, Roobol S, Rother M, van der Gulden H, et al.
Cancer Res
. 2021 Sep;
81(24):6171-6182.
PMID: 34548335
The tumor suppressor gene encodes a multidomain protein for which several functions have been described. These include a key role in homologous recombination repair (HRR) of DNA double-strand breaks, which...
9.
Snijders K, Feher A, Tancos Z, Bock I, Teglasi A, van den Berk L, et al.
Arch Toxicol
. 2021 Sep;
95(10):3285-3302.
PMID: 34480604
Tagging of endogenous stress response genes can provide valuable in vitro models for chemical safety assessment. Here, we present the generation and application of a fluorescent human induced pluripotent stem...
10.
Ter Braak B, Niemeijer M, Wolters L, Le Devedec S, Bouwman P, van de Water B
Mutagenesis
. 2021 Aug;
37(2):130-142.
PMID: 34448005
In vitro assessment of mutagenicity is an essential component in the chemical risk assessment. Given the diverse modes of action by which chemicals can induce DNA damage, it is essential...